294 related articles for article (PubMed ID: 27385239)
1. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
[TBL] [Abstract][Full Text] [Related]
2. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
4. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
5. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
6. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
7. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
8. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
9. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
Nemlekar P; Shepherd M; Lawson K; Rush S
J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
11. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
12. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
13. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
14. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
15. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
[TBL] [Abstract][Full Text] [Related]
16. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.
Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP
Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168
[TBL] [Abstract][Full Text] [Related]
17. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
Bonakdar Tehrani A; Cunningham PJ
Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
19. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
20. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]